In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

Boogie2988 (born Steven Jason Williams) claimed in November 2022 that he had been diagnosed with polycythemia vera, a type of ...

Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia ...

Hi. I'm Ron. I'm a polycythemia patient, and I've had the disease for over 25 years. I was originally diagnosed at the age of 38. And I'm here to talk to you about symptom management and talking ...

Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end ...

Suffering a stroke allowed doctors to diagnose and treat a rare cancer flag football coach Cory Beal was suffering from ...

A lifelong Ocean Grove resident who was heavily involved in the plumbing union is being remembered after losing his battle ...

Image Source: Zacks Investment Research Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to ...

Topline Data from 52-week Phase 3 Study Expected in Late 2025 –CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, ...